Research and Development in Biotechnology

AWARD OF CONTRACT TO MANAGE AND OPERATE THE NATIONAL RENEWABLE ENERGY LABORATORY

IGF::OT::IGF

TERMINATION SETTLEMENT PROPOSAL DEADLINE FOR FDA LICENSURE OF A BIOSCAVENGER PROPHYLAXIS.

IGF::OT::IGF

THE PURPOSE OF THIS MODIFICATION IS TO DEOBLIGATE FUNDS FROM CLIN 0011 (OPTION 10) AND UPDATE FAR & HHSAR CLAUSES PER EXECUTIVE ORDER AND FAR/HHSAR CLASS DEVIATIONS

THE PURPOSE OF MODIFICATION P00014 IS TO DE-OBLIGATE CANCELING FUNDS

THE PURPOSE OF THIS MODIFICATION IS TO CLOSE OUT THE CONTRACT IN ITS ENTIRETY. 1. CHIMERIX IS NO LONGER IN OPERATION AND THEREFORE, THIS CONTRACT CAN BE DEOBLIGATED AND CLOSED OUT IN ITS ENTIRETY. NO CONTRACTOR RELEASE OF CLAIMS NOR A CONTRACTING O

DATA COORDINATING CENTER FOR THE BEST PHARMACEUTICALS FOR CHILDREN ACT

ADVANCEMENT OF HEMAMAX TOWARDS BLA SUBMISSION FOR THE MITIGATION OF HSARS UNDER THE FDA ANIMAL RULE

IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH.

THE PURPOSE OF THIS NO MODIFICATION IS TO CLOSE OUT CONTRACT NO. HHSO100201000008C IN ITS ENTIRETY.

CONTRACTOR-ACQUIRED PROPERTY (CAP) AND GOVERNMENT FURNISHED EQUIPMENT

TO ADMINISTRATE DE-OBLIGATE UNEXPENDED AND EXPIRING FISCAL YEAR 2021 FUNDING IN ACCORDANCE WITH 31 U.S.C. SECTION 1552 (A), IN PREPARATION FOR SEPTEMBER 30, 2026, CLOSING OF THE PERIOD OF AVAILABILITY OF THESE FISCAL YEAR FUNDS.

THIS REQUIREMENT IS FOR COMMERCIALIZATION OF FREEZE DRIED PLASMA PRODUCT.

IGF::OT::IGF OTHER FUNCTIONS NINDS EPILEPSY THERAPY SCREENING PROGRAM

THE PURPOSE OF THIS MODIFICATION IS TO DEOBLIGATE CANCELLING FUNDS IN THE AMOUNT OF $2,539,496.23 AS FOLLOWS: 1. $1,050,656.17 FROM CLIN 0013 2. $1,488,840.00 FROM CLIN 0014 3. $0.06 FROM CLIN 0012

NEW PBP INHIBITORS IMPERVIOUS TO BETA-LACTAMASES

IGF::OT::IGF CONTRACEPTIVE CLINICAL TRIAL NETWORK - MALE SITES - CONTRACEPTIVE EFFICACY CLINICAL TRIALCONTRACT # HHSN275201300024I/HHSN27500007

THE PURPOSE OF THIS BILATERAL CONTRACT MODIFICATION IS TO DEOBLIGATE UNUSED FUNDS AND CLOSE OUT THE CONTRACT.

EOI::EO: RADICAL TRANSPARENCY ABOUT WASTEFUL SPENDING::EOI UNILATERAL MODIFICATION TO CORRECT FPDS-NG REPORTING IAW ACQUISITION ALERT 2025-04 AMENDMENT 2.

THIS TASK ORDER IS FOR THE DEVELOPMENT OF A PROTOCOL, CLINICAL TRIAL IMPLEMENTATION, CLOSEOUT AND ANALYSIS OF A PHASE 2 CLINICAL TRIAL TO EVALUATE THE EFFICACY OF RMENB+OMV NZ (BEXSERO, GSK) IN PREVENTING N. GONORRHOEAE INFECTION.

REGENERON ANTI-MERS ANTIBODY THERAPEUTICS PROGRAM DEVELOPMENT

SUPPLEMENTAL ADVANCED DEVELOPMENT TASKS ZEBOV VACCINE

UPDATE CONTRACTING OFFICER AND INDIRECT RATES

SCREENING POTENTIAL MEDICAL COUNTERMEASURES TO CHLORINE GAS IN A SMALL ANIMAL MODEL.